Cue Health on Wednesday afternoon announced that revenues for the third quarter beat both Wall Street expectations and previous guidance from the firm.

Meridian Bioscience reported on Tuesday that its fiscal fourth quarter revenues declined 14 percent year over year.

Agilent Technologies said after the close of the market on Monday that its fiscal fourth quarter revenues grew 11 percent year over year and beat the consensus Wall Street estimate.

SomaLogic reported on Monday that it has recorded a one-time licensing royalty of $21.2 million related to a deal with New England Biolabs.

Recently, EasyDiagnosis disclosed its third quarterly report, the company achieved revenue of 7.47 billion CNY in the first three quarters, an increase of 285.38% year-on-year; achieved net profit of 3.838 billion CNY, an increase of 281.76% year-on-year.

Bruker reported before the open of markets on Thursday that revenues in the third quarter rose 5 percent year over year.

In the evening of October 24, Beijing Hotgen Biotech Co., Ltd. (stock code: 688068) released its third quarter report for 2022. In the third quarter, Hotgen 's revenue and net profit continued to jump, achieving CNY 963 million revenue with a year-on-year increase of 391.95%

Hologic reported after the close of the market on Monday that a continued decline in sales of COVID-19 assays and ongoing difficulties securing semiconductor chips contributed to an overall 28 percent year-over-year decline in its fiscal fourth quarter revenues.

Myriad Genetics reported on Tuesday that its third quarter revenues fell 7 percent year over year primarily due to currency translations and change of estimates in diagnostic test cash collection, and non-recurring milestone payments.

BioMérieux announced on Wednesday that its third quarter revenues rose approximately 3 percent year over year due in part to unexpectedly strong sales in its BioFire product line.